insurance won't cover semaglutide and Health Landry vetoes weight-loss drug insurance

Research Evidence Comparison# Retatrutide Research# Phase 1 : First-in-human study established safety and pharmacokinetics Phase 2 (n=338) : Published in NEJM (2023), demonstrated dose-dependent weight loss up to 24.2% at 48 weeks with 12 mg dose

Picca, S., Bartuli, A

There is also the risk of lithium toxicity when taken in high dosages

(If it doesnt, press the pen more firmly against your skin.) As the pen continues delivering your dose of Wegovy, you will hear a second click

This way, you can ensure youre getting the best value while managing your health effectively

People with Type 2 diabetes are also at risk of experiencing hypoglycemia when taking Wegovy